Takeda Pharmaceutical Co. $TAK Shares Sold by UBS Group AG

Key Points

• UBS Group AG cut its Takeda stake by 30.0% in Q4, selling 1,770,446 shares and retaining 4,123,523 shares (about 0.13% of the company) valued at roughly $64.3 million, per its latest Form 13F.
• Several brokerages have recently turned more positive—Morgan Stanley started coverage with an "overweight" rating, Sanford C. Bernstein upgraded to "outperform" and Wall Street Zen to "strong-buy"—leaving the stock with an average rating of Moderate Buy (two Buys, two Holds).
• Takeda opened near $16.57 with a market cap of $52.72 billion, a P/E of 69.02, a 52-week range of $12.99–$18.90, and institutional investors owning about 9.17% of the shares.

UBS Group AG lowered its position in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 30.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,123,523 shares of the company's stock after selling 1,770,446 shares during the quarter. UBS Group AG owned 0.13% of Takeda Pharmaceutical worth $64,286,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in TAK. Private Trust Co. NA increased its position in shares of Takeda Pharmaceutical by 84.7% in the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company's stock valued at $27,000 after buying an additional 783 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its position in shares of Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company's stock valued at $55,000 after buying an additional 1,292 shares in the last quarter. Advisory Services Network LLC purchased a new position in shares of Takeda Pharmaceutical in the third quarter valued at $74,000. Farther Finance Advisors LLC increased its position in shares of Takeda Pharmaceutical by 24.5% in the third quarter. Farther Finance Advisors LLC now owns 7,001 shares of the company's stock valued at $102,000 after buying an additional 1,378 shares in the last quarter. Finally, Global Trust Asset Management LLC purchased a new position in shares of Takeda Pharmaceutical in the third quarter valued at $110,000. Hedge funds and other institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Down 0.3%

TAK opened at $16.57 on Tuesday. The company has a quick ratio of 0.65, a current ratio of 1.19 and a debt-to-equity ratio of 0.56. The firm has a market cap of $52.72 billion, a P/E ratio of 69.02 and a beta of -0.06. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.90. The business's fifty day simple moving average is $17.94 and its 200 day simple moving average is $16.27.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TAK. Morgan Stanley began coverage on Takeda Pharmaceutical in a research report on Tuesday, January 13th. They issued an "overweight" rating for the company. Sanford C. Bernstein upgraded Takeda Pharmaceutical from a "market perform" rating to an "outperform" rating in a research report on Wednesday, April 8th. Zacks Research upgraded Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 3rd. Wall Street Zen raised Takeda Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Saturday, April 11th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Takeda Pharmaceutical in a research note on Wednesday, April 29th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy".

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited NYSE: TAK is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.